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Burkitt lymphoma (BL) and diffuse large B cell lym-
p h o m a( D L B C L )a r ea g g r e s s i v ef o r m so fl y m p h o m ai n
adults and demonstrate overlapping morphology, immu-
nophenotype and clinical behavior. The risk of develop-
ing these tumors increases ten to hundred-fold in the
setting of HIV infection. The genetic causes and the
role of specific mutations, especially in the setting of
HIV, are largely unknown.
The decoding of the human genome and the advent of
high-throughput sequencing have provided rich oppor-
tunities for the comprehensive identification of the
genetic causes of cancer. In order to comprehensively
identify genes that are recurrently mutated in immune-
competent DLBCL and BL, we obtained a total of 92
cases of DLBCLs and 40 cases of BL. These cases were
compared to a set of 5 DLBCLs and BL tumors derived
from patients with HIV. The DLBCL cases were divided
into a discovery set (N=34) and a prevalence set (N=61).
The Burkitt cases were also divided into discovery and
prevalence sets (N=15, N=45 respectively). For each of
the discovery set cases we also obtained paired normal
tissue. We performed whole-exome sequencing for all of
these using the Agilent solution-based system of exon
capture, which uses RNA baits to target all protein cod-
ing genes (CCDS database), as well as ~700 human
miRNAs from miRBase (v13). In all, we generated over
6 GB of sequencing data using high throughput sequen-
cing on the Illumina platform.
We identified a total of 432 genes that were recur-
rently mutated in DLBCL and BL. We found that each
tumor had an average of 20 gene alterations, which is
fewer than most other solid tumors sequenced to date.
Commonly implicated biological processes comprising
these genes included signal transduction (e.g. PIK3CD,
PDGFRA), immune response (e.g. B2M, CD83, IRF8)
and chromatin modification (e.g. MLL3, SETD2). We
found that lymphomas that arose in the setting of HIV
had fewer mutations overall and had a paucity of muta-
tions related to immune response.
These data implicate the depressed immune response
by HIV as a contributing risk factor for the development
of lymphomas and suggest that HIV lymphomas are
genetically less complex than their immune competent
counterparts. This study represents one of the largest
applications of exome sequencing in cancer, and provides
early clues to the genetic causes of HIV-lymphomas.
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